Date: 2015-06-18
Type of information: Collaboration agreement
Compound:
Company: Axxam (Italy) MD Anderson Cancer Center (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism:
Disease:
Details: * On June 18, 2015, Axxam announced that the company has entered into a multiyear collaboration with the Institute for Applied Cancer Science (IACS) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify lead chemical matters against novel oncology targets provided by MD Anderson. The collaboration leverages Axxam’s expertise in assay development, Axxam’s fully automated screening platforms and access to Axxam’s novel compound collection AxxDiv2.
Financial terms:
Latest news:
